Oncotelic Therapeutics (OTCQB: OTLC) announced that its 45%-owned joint venture, Sapu Nano, presented new data at the 2025 San Antonio Breast Cancer Symposium. The data show that Sapu Nano's Deciparticle nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics into sub-20 nm nanoparticles suitable for intravenous delivery. The drugs tested include macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams, and polyketides.
The company stated that these findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities, enabling rapid translation to Phase 1 supply. CEO Dr. Vuong Trieu commented that the results position Deciparticle as a modular engine for multiple oncology, immunology, and peptide drug candidates, with Sapu003 representing the first of a broader pipeline. The full press release is available at https://nnw.fm/b0Qps.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company benefits from the portfolio of inventions created by CEO Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. In addition to its internal programs, Oncotelic licenses and codevelops drug candidates through joint ventures. The company owns 45% of GMP Bio, a joint venture under Trieu's leadership advancing its own pipeline of drug candidates that complement Oncotelic's strategic position in oncology and rare disease therapeutics. For more information, visit the company's newsroom at https://nnw.fm/OTLC.
The Deciparticle platform's ability to formulate diverse hydrophobic drugs into nanoparticles under 20 nm is significant because many promising therapeutic candidates, particularly in oncology and immunology, are hydrophobic and difficult to deliver effectively. The platform's cGMP readiness and ISO-5 manufacturing support could accelerate the development of these drugs into clinical trials. Sapu Nano's data suggest that Deciparticle could become a standard tool for formulating challenging drug candidates, potentially expanding the pipeline of treatable conditions.
This announcement reinforces Oncotelic's strategic focus on innovative delivery technologies and its joint venture model to leverage external expertise. The progress of Sapu Nano and the Deciparticle platform may open new avenues for drug development, offering solutions to formulation challenges that have historically hindered the clinical translation of hydrophobic compounds.
